Home
Live Updates
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval : vimarsana.com
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
– FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a...
Related Keywords
Stevenm Harasym ,
Clintt Allen ,
Scott Norberg ,
Precigen Adenoverse ,
Kim Mcclellan ,
National Institutes Of Health ,
Prnewswire Precigen Inc ,
Recurrent Respiratory Papillomatosis Foundation ,
Exchange Commission ,
Immunotherapy Clinical Program ,
Nasdaq ,
Precigen Inc ,
Drug Administration ,
Complete Response ,
Therapy Designation ,
Orphan Drug Designation ,
National Institutes ,
Recurrent Respiratory Papillomatosis ,
Advancing Medicine ,
Beta Trap ,
Breakthrough Therapy Designation ,
Annual Report ,
Otolaryngol Head Neck Surg ,
Developing Country Review ,
Health Med Ther ,
Head Neck Surg ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.